Comparison of single-use and reusable flexible ureteroscope for renal stone management: a pooled analysis of 772 patients.

Flexible ureteroscopy is a common therapy for patients with renal calculi. In recent years, the prevalence of single-use flexible ureteroscope (FURS) use has been on the rise. Thus, several trials have been conducted to compare the efficacy between single-use and reusable FURS. The aim of this meta-analysis was to systematically assess the effectiveness and safety of single-use vs. reusable FURS in treating renal stones. PubMed, Web of Science, Cochrane Library and EMBASE were researched to identify relevant studies up to September 2019. Article selection was performed through the search strategy based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses criteria. The Newcastle-Ottawa Scale was applied to assess the methodological quality of non-randomized controlled trials, and the methodological quality of randomized controlled trials was evaluated using the Jadad scale. A total of five studies with 772 patients were included in the meta-analysis, including two randomized controlled trials, two single-centre prospective studies, and one prospective case-control trial. The pooled results showed that single-use FURS was associated with a higher stone-free rate (SFR) (OR: 1.50; 95% CI, 1.06-2.12; P=0.02) than reusable FURS. A significant difference was noted in operative time, and single-use FURS was associated with a longer operative duration (MD: 7.39 min; 95% CI, 1.75-13.03; P=0.01). No significant difference was noted in perioperative complications (OR: 0.97; 95% CI, 0.56-1.70; P=0.92). Subgroup analysis showed no significant difference in urinary tract infection (OR: 0.80; 95% CI, 0.44-1.46; P=0.46), stent migration (OR: 0.56; 95% CI, 0.19-1.65; P=0.30) or acute kidney injury (OR: 0.76; 95% CI, 0.16-3.57; P=0.73). Single-use FURS is an effective and safe alternative to reusable FURS for the management of renal stones. 2021 Translational Andrology and Urology. All rights reserved.

Introduction

Urinary stone disease, or urolithiasis, is one of the most common diseases in the urology field and affects approximately 12% of the world’s population at some stage in their lifetime (1). Transformation of lifestyle factors, such as decreases in physical activity, has increased the prevalence of urolithiasis in recent decades (2). Widely used therapy procedures include extracorporeal shockwave lithotripsy (SWL), percutaneous nephrolithotomy (PCNL) and flexible ureteroscope (FURS) (3,4). Studies worldwide have shown an increasing trend for FURS in the treatment of renal stones (5). With technical and optical improvements, FURS has become a more widespread approach for intrarenal stone removal. Furthermore, in some countries, FURS is used as a first-line treatment modality for renal stones <20 mm (4).

The first record of the traditional FURS was provided by Marshall in 1964 (6). It is mostly used for the treatment of upper urinary stones <20 mm in size and has stone-free rates (SFRs) up to 90% (7). Although traditional reusable FURS is less invasive has less blood loss and shorter hospital stays compared with PCNL (8), some constraints remain, including a high initial purchase cost, high maintenance costs, and a risk of cross-infection, which resulted in the development of single-use FURS (9,10).

When Bagley pioneered the disposable FURS for accessing the upper urinary tracts in 1987 (11), it was only used to monitor fragments after lithotripsy and diagnose anatomical abnormalities of the upper urinary tract. Over the last few years, there have been encouraging results on the improvement of single-use FURS. The results of many in vitro trials of single-use FURS were comparable to those of reusable FURS in terms of optics, deflection, and irrigation flow (9,12,13).

Previous studies have indicated that reusable FURS rated highly in terms of manoeuvrability and image quality (14,15). Clinical studies have indicated that single-use digital FURS performed comparably to current reusable FURS in terms of the SFR, operative time and complication rate (16). Hence, we performed a meta-analysis to assess the effectiveness and safety of single-use FURS versus reusable FURS in the treatment of stone disease in patients. We present the following article in accordance with the PRISMA reporting checklist (available at: http://dx.doi.org/10.21037/tau-20-1009).

Methods

Data sources and search

A literature search was performed for all studies published before September 2019 in the PubMed, Web of Science, Cochrane Library and EMBASE online databases. The search strategy was performed with the following search terms: (flexible ureteroscopes OR retrograde intrarenal surgery OR FURS OR RIRS) AND (single-use flexible ureteroscopes OR disposable flexible ureteroscopes OR single-use FURS OR disposable FURS) AND (renal calculi OR renal stones OR nephrolithiasis OR stone disease). References of original studies were also screened to identify additional reports.

Study selection

Article selection was performed independently in accordance with the process based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (17). The inclusion criteria for the final selected studies were as follows: (I) original comparative studies reporting at least one of the following outcomes for both single-use FURS and reusable FURS: SFR, operation time, perioperative complications and (II) the full text of the study was available in English. However, studies that published as conference abstracts or posters; studies that failure to provide one of these outcomes of interest; or studies that including paediatric patients (<18 years old) were excluded.

Quality assessment

According to the widely used criteria provided by the Oxford Centre for Evidence-Based Medicine, the methodological quality of the non-randomized retrospective case-control studies was assessed using the modified Newcastle-Ottawa Scale (NOS), which assesses a maximum of 9 points for the lowest risk of bias in 3 domains: (I) selection; (II) comparability; and (III) exposure and outcomes. A study was considered “high quality” with >6 points and “low quality” with <3 points.

The Jadad scale (also known as the Oxford quality scoring system) was applied to evaluate the methodological quality of RCTs. A study was considered “high-quality” with >3 points, and studies with scores <2 points were considered “low quality”.

Data extraction and statistical analysis

Two independent investigators extracted the following information for each study: first author’s name, year of publication, number of patients (single-use FURS group and reusable FURS group), mean operation time, stone-free rate and complication rate. To extract the data, a standardized Excel file was used. We chose the article with the most recent data when the same trial appeared in different publications. Meta-analyses of comparable data were performed with Review Manager Software (RevMan V5.3, Cochrane Collaboration, Oxford, UK). The experimental group was a single-use FURS group, while the control group was a reusable FURS group. For the binary variables, including stone-free rate and incidence of complications, odds ratios (ORs) were employed, and for the continuous parameters, including operative duration, mean differences (MDs) were employed. We used forest plots to express the results of the meta-analysis. Heterogeneity among the included studies was assessed with a chi-square test and I2 statistic, in which I2>50% or P<0.10 was considered statistically significant heterogeneity. Where heterogeneity among studies was not detected, pooled estimates were calculated with a fixed-effect model (Mantel-Haenszel method). When there was evidence of heterogeneity, a random-effect model (DerSimonian-Laird method) was used. To explore the reliability of the results, sensitivity analysis was applied by omitting a specific study each time. To assess publication bias, a funnel plot was routinely performed.

Results

Search results and study characteristics

As illustrated in , 128 studies were initially identified, and we excluded 123 articles, including one cadaveric feasibility study, one porcine feasibility study and forty-three irrelevant studies. Five studies were excluded because they were cost comparison analyses, and five studies were excluded because they compared mechanical, optical and irrigation properties. Six-eight studies were excluded because they were comments or reviews. We found one additional record identified through reference lists, and a total of five trials were eligible for final inclusion, all of which were full-text articles. In , we summarize the baseline characteristics of the 5 studies, such as age, sex ratio, body mass index, stone burden, and model of single-use FURS and reusable FURS. In a study by JK, two different models of single-use FURS were available (Disposable 1: Lithovue Disposable 2: PU3022A). The definition of SFR in the included studies was inconsistent, and one study reported that a residual fragment <2 mm in diameter was considered an insignificant clinical fragment. The rest of the included studies defined a residual fragment <4 mm as an insignificant clinical fragment. CT (computer tomography), BUS (B ultrasound) and KUB (X-ray of the kidney, ureter and bladder) were used to determine the SFR.

Figure 1

PRISMA flow diagram of study selection.

Table 1

Characteristics of patients in the studies included

References (year)	Country	Design	FURS			Cases (M/F), n			Age (years)			BMI			Stone size (mm)		Scores
			Single-use	Reusable		Single-use	Reusable		Single-use	Reusable		Single-use	Reusable		Single-use	Reusable
Kam [2019]	Australia	Prospective, single-center, cross-sectional	Lithovue	URF-V2		(41/14) 55	(39/25) 64		53.5 (46.2–60.7)	53.3 (47.6–59.0)		NR	NR		14.7 (112–18.1)	13.3 (11.0–15.6)	6 (NOS)
			PU3022A	URF-V2		(21/10) 31	(39/25) 64		54.1 (46.0–62.2)	53.3 (47.6–59.0)		NR	NR		12.8 (9.7–15.9)	13.3 (11.0–15.6)
Qi [2019]	China	RCT	Zebrascope	URF-V		(46/17) 63	(45/18) 63		51.84±13.16	53.25±12.11		26.07±4.55	25.84±3.56		NR	NR	6 (Jadad)
Mager [2018]	Germany	Cohort	Lithovue	Flex-x2s/Flex-xc		(48/20) 68	(43/25) 68		54±17	59±16		NR	NR		NR	NR	6 (NOS)
Usawachintachit [2017]	American	Case control	Lithovue	URF-P6		(61/54) 115	(31/35) 65		55.8±15.1	50.5±12.6		29.1±8.6	30.6±9.6		14.7±9.9	16.3±12.2	7 (NOS)
Ding Jie [2015]	China	RCT	Polyscope	URF-V2		(102/78) 180	(107/73) 180		50.5±12.8	51.1±13.7		NR	NR		NR	NR	5 (Jadad)

FURS, flexible ureteroscope; M/F, male/female; BMI, body mass index; NR, not reported; RCT, randomized controlled trial; NOS, the Newcastel-Ottawa Scale.

Study quality

According to the NOS, the methodological quality of two single-centre prospective trials and one prospective case-control trial were judged to be high, ranging from 6–7 (Table S1), and Jadad scores for 2 RCTs ranged from 5 to 6 (Table S2). High quality was observed among all included studies.

Operative time

Four included studies provided enough data available on operative time (14,18-20). In Kam’s study, two different models of single-use FURS were compared with the same traditional FURS. Significant heterogeneity (I2=89%) among studies was identified; thus, a random-effect model was used. The results of the meta-analysis indicated that single-use FURS was associated with a significantly longer operative time (MD: 7.39 min; 95% CI, 1.75–13.03; P=0.01) (). Since there are two types of single-use FURS: single-use digital FURS and single-use fiberoptic FURS and 3 of 4 studies used the single-use digital FURS, a subgroup analysis was conducted. There is no significant difference between the single-use digital FURS and reusable FURS (MD: 6.32 min; 95% CI, −1.04 to 13.68; P=0.09) (). In the study by QS, the operative time was defined as the time from ureteroscope insertion until the end of Foley catherization. However, in the study by Ding et al., the operation time was recorded from the insertion of a rigid ureteroscope to the placement of a double J stent.

Figure 2

Forest plots illustrating meta-analysis of mean operative time. Single-use FURS was associated with a longer operative time compared with reusable FURS.

Figure 3

Forest plots illustrating meta-analysis of mean operative time. No significant difference between the single-use digital FURS and reusable FURS with regard to operative time.

SFR

Four trials with 686 participants described the SFR (7,18-20), and pooled results indicated that compared to reusable FURS, single-use FURS provided a significantly higher SFR (OR: 1.50; 95% CI, 1.06–2.12; P=0.02) () without detection of statistical heterogeneity (I2=0%). In the studies by Qi et al. and Ding et al., “stone-free” status was defined as no residual stones or stones ≤4 mm, while in Mager’s research, stone-free status was assessed intraoperatively by the surgeon’s endoscopic and fluoroscopic view. In the study by Usawachintachit et al., residual stone status was classified as stone free (no fragments present) or insignificant residual fragment (residual fragments <2 mm).

Figure 4

Forest plots illustrating meta-analysis of stone-free rate. The stone-free rate of single-use FURS was superior to that of reusable FURS.

Perioperative complications

Four included studies with 842 participants had enough data relevant to perioperative complications (14,18-20), and ORs were used for statistical analysis. Due to the detection of high statistical heterogeneity (I2=56%), a random-effect model was used. The pooled results indicated no significant difference between the two groups with respect to perioperative complications (OR: 0.97; 95% CI, 0.56–1.70; P=0.92) (). In the studies by Kam et al. and Usawachintachit et al., perioperative complications were classified using the Clavien-Dindo classification system. Next, we separately analysed complications. The analysis showed no significant difference between the two groups related to acute renal injury (OR: 0.76; 95% CI, 0.16–3.57; P=0.73) (), urinary tract infection (OR: 0.80; 95% CI, 0.44–1.46; P=0.46) () or stent migration (OR: 0.56; 95% CI, 0.19–1.65; P=0.30) ().

Figure 5

Forest plots illustrating meta-analysis of (A) perioperative complications (B) acute renal injury (C) urinary tract infection (D) stent migration. No significant difference between the single-use digital FURS and reusable FURS with regard to perioperative complications.

Publication bias and sensitivity analyses

The funnel plot for the SFR are shown in . To assess the effect of a single study on the overall estimate, sensitivity analyses were conducted by excluding each study sequentially, one at a time (). In our meta-analysis, there were no studies that could influence the summary of risk estimates.

Figure 6

Funnel plot of comparison regarding stone-free rate.

Figure 7

Sensitivity analysis of comparison regarding (A) operative time, (B) stone-free rate and (C) perioperative complications.

Discussion

To date, this study is the latest comprehensive meta-analysis to investigate the efficacy of single-use and reusable FURS. Based on five studies, the results from our meta-analysis suggested that there was no significant difference between the two groups in terms of perioperative complication rate. Single-use FURS was associated with a higher stone free rate but a longer operative time compared with reusable FURS. However, Subgroup analysis indicated that there was no significant difference between the single-use digital FURS and reusable FURS regarding operative time. The potential reason for single-use FURS having a longer operative time may be its lower image quality scores. JK found that the reusable FURS outperformed the single-use FURS in terms of visibility rate on a 5-point Likert scale (14), which is consistent with previous researches (15,21,22). As is shown in the , the type of single-use and reusable FURS compared in each study were different. LithoVue, PU3022A, ZebraScope are single-use digital FURS, PolyScope is single-use fiberoptic FURS. Notably, the digital FURS usually perform better than fiberoptic FURS in terms of image quality. The research indicated the mean operative time was significantly longer in the fiberoptic FURS compared with digital FURS (23). Furthermore, the operation of single-use FURS is requires longer training under guidance, a learning curve showed that with the increase in the amount of operations, the mean operative time gradually decreased (18).

A study conducted by Bell et al. compared the LithoVue with URF-P5/P6 and the digital Flex Xc, found that the LithoVue scored lower on most user comfort and maneuverability (21). In the study by Qi et al. (20), the authors found that the nitinol basket usage rate of single-use FURS was higher than that of reusable FURS. It seems that single-use FURS has superior operability, which is responsible for the higher SFR.

Radical changes have taken place in the field of endourology and stone treatment due to technological innovation during recent decades. FURS has become an effective and safe choice for renal stones due to better access and visualization of the upper urinary tract. Furthermore, since it is less invasive than PCNL, FURS is considered a first-line option for kidney stones, particularly for stones <20 mm (4). Even so, this technique still has several disadvantages, including the frequent need for repair, high cost of acquisition and maintenance and high risk of cross infection. As a consequence, the single-use ureteroscope has gained widespread popularity aiming to offer solutions to the possibility of contamination and high cost issues. To date, there are more than 10 different single-use FURSs on the market, with different characteristics, including LithoVue, PolyScope, PU3022, Semi-Flex Scope Yc-FR-A and so on (24).

Emiliani et al. published a review of the disposable FURS in 2016 and analysed the characteristics, merits and disadvantages of disposable FURS (24). LithoVue, which is called “the actual single-use FURS”, was introduced in Europe in 2015 and launched in the United States in 2016 with the purpose of reducing expenses associated with reusable FURS (25). Benchtop, porcine and cadaveric studies demonstrated that LithoVue is not inferior to reusable FURS when image quality and manoeuvrability were compared (26,27).

The PolyScope is fiberoptic and composed of a single-use flexible catheter (26). It has a modular design to facilitate the repair or disposal of individual components, and the scope contains 10,000-pixel fiberoptic bundles (28). An important limitation of PolyScope is its unidirectional deflection of up to 180°. Gu et al. analysed the clinical performance of PolyScope in a series of 86 patients and reported a SFR of 89.5% and an acceptable safety profile (29).

Uscope PU3022, which is the latest Uscope version, has the same degree of deflection and working channel position as LithoVue. Compared with LithoVue, Pusen’s scopes are almost 50% lighter. Most of the previous studies were focused on physical characteristics. Deininger et al. investigated flow rate, deflection, illumination, and intrapelvic pressure on two single-use and one reusable FURS in a porcine kidney model (15). Higher flow rates were observed in single-use FURS, which was considered to be associated with higher intrapelvic pressure.

It has been reported that the complication rate of FURS is approximately 10–15% (30). With the purpose of evaluating the clinical outcomes with a Chinese disposable FURS (YouCare Tech), a prospective study was conducted in a single centre in China by Wang et al. with a total of 653 patients involved in the trial. The results showed that the median operative time was 52 min, the overall SFR was 95.2%, and the complications, such as gross haematuria, were mild (30). The discordance of the assessment of SFR resulted in the different results of the SFR. Mager et al. reported a higher SFR in the trial group than in the control group (85% vs. 82%) (7). However, in MU’s study, the SFR of single-use FURS was 60% (31). Bader et al. examined the clinical outcome in patients undergoing ureteronephroscopy by PolyScope, and the resulting SFR was 87.5% (19). The case-control study performed by Usawachintachit et al. found that the overall mean procedure time of single-use FURS was 10 min shorter than that of reusable FURS (19). Conversely, Kam et al. found that single-use FURS was 10 min longer than that of the reusable FURS group (14). However, JK thought that the lower image quality associated with single-use FURS was responsible for this difference, although the operative duration is closely linked with the experience of the surgeon (14). A systematic search was performed for studies evaluating single-use FURS in the setting of urinary tract stone disease by NFD in 2018 (16). The studies consisted of one RCT, three single-centre prospective studies, two multi-institutional prospective studies, one cadaveric feasibility study, one porcine feasibility study and three comparative benchtop studies. The mechanical, optical and irrigation properties of single-use FURS were investigated, and the clinical effectiveness of different single-use FURSs was compared with that of reusable FURSs. The study showed that there were no significant differences in procedure duration, stone clearance or complication rates when single-use FURS and reusable FURS were compared. However, in our study, we excluded cadaveric studies and porcine studies.

Many cost-effectiveness analyses are performed that seem to indicate a lack of economic disadvantage in the employment of single-use FURS, particularly in low-volume centres. A single-centre retrospective analysis was conducted to compare the actual cost of reusable FURS with LithoVue in 2017 by Ozimek et al. (32), who concluded that, for high volume centres, it is a noneconomic option to shift from reusable FURS to disposable FURS. A systematic literature review on single-use FURS performance was performed in 2020 by Ventimiglia et al. (33), who introduced the available and marketed single-use FURS, the advantages and drawbacks of single-use FURS and the cost-effectiveness of single-use FURS. Thus, the wide adoption of single-use FURS is restricted because of its high cost and substantial lack of evidence.

There are several potential limitations to this meta-analysis that should be considered. First, only 5 trials met the inclusion criteria, and among the 5 studies, only 2 were RCTs, while the others were cohort studies or case-control studies. Cohort data are associated with bias caused by patient selection. Second, studies with a small sample size were more likely to overestimate the treatment effect than those with larger sample sizes. Third, SFR was assessed by different methods. These limitations may complicate the interpretation of our findings.

Conclusions

In conclusion, the findings of the present meta-analysis indicated that single-use FURS had a higher SFR but longer operative time in comparison with reusable FURS. The perioperative complication rates between the two groups were comparable. Therefore, we propose that single-use FURS may be an alternative therapy to reusable FURS, with acceptable efficacy and complication rates for renal stones. However, considering the potential limitations of this study, further large scale, well performed RCTs are required to verify our findings.

The article’s supplementary files as